Imaging Biomarkers as Predictors for Breast Cancer Death

被引:13
|
作者
Wu, Wendy Yi-Ying [1 ]
Tabar, Laszlo [2 ]
Tot, Tibor [3 ]
Fann, Ching-Yuan [4 ]
Yen, Amy Ming-Fang [5 ]
Chen, Sam Li-Sheng [5 ]
Chiu, Sherry Yueh-Hsia [6 ]
Ku, May Mei-Sheng [7 ]
Hsu, Chen-Yang [7 ]
Beckmann, Kerri R. [8 ]
Smith, Robert A. [9 ]
Duffy, Stephen W. [10 ]
Chen, Hsiu-Hsi [7 ]
机构
[1] Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden
[2] Cty Hosp Falun, Dept Mammog, Falun, Sweden
[3] Cty Hosp Falun, Dept Pathol, Lab Med Dalarna, Falun, Sweden
[4] Kainan Univ, Taoyuan, Taiwan
[5] Taipei Med Univ, Taipei, Taiwan
[6] Chang Gung Univ, Taoyuan, Taiwan
[7] Natl Taiwan Univ, Taipei, Taiwan
[8] Univ South Australia, Adelaide, SA, Australia
[9] Amer Canc Soc, Atlanta, GA 30329 USA
[10] Queen Mary Univ London, London, England
关键词
CLASSIFICATION; WOMEN;
D O I
10.1155/2019/2087983
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. To differentiate the risk of breast cancer death in a longitudinal cohort using imaging biomarkers of tumor extent and biology, specifically, the mammographic appearance, basal phenotype, histologic tumor distribution, and conventional tumor attributes. Methods. Using a prospective cohort study design, 498 invasive breast cancer patients diagnosed between 1996 and 1998 were used as the test cohort to assess the independent effects of the imaging biomarkers and other predictors on the risk of breast cancer death. External validation was performed with a cohort of 848 patients diagnosed between 2006 and 2010. Results. Mammographic tumor appearance was an independent predictor of risk of breast cancer death (P=0.0003) when conventional tumor attributes and treatment modalities were controlled. The casting type calcifications and architectural distortion were associated with 3.13-fold and 3.19-fold risks of breast cancer death, respectively. The basal phenotype independently conferred a 2.68-fold risk compared with nonbasal phenotype. The observed deaths did not differ significantly from expected deaths in the validation cohort. The application of imaging biomarkers together with other predictors classified twelve categories of risk for breast cancer death. Conclusion. Combining imaging biomarkers such as the mammographic appearance of the tumor with the histopathologic distribution and basal phenotype, accurately predicted long-term risk of breast cancer death. The information may be relevant for determining the need for molecular testing, planning treatment, and determining the most appropriate clinical surveillance schedule for breast cancer patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
    Molinari, Chiara
    Matteucci, Federica
    Caroli, Paola
    Passardi, Alessandro
    CLINICAL COLORECTAL CANCER, 2015, 14 (04) : 227 - 238
  • [42] Biomarkers in preclinical cancer imaging
    Bernsen, Monique R.
    Kooiman, Klazina
    Segbers, Marcel
    van Leeuwen, Fijs W. B.
    de Jong, Marion
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (04) : 579 - 596
  • [43] Biomarkers in preclinical cancer imaging
    Monique R. Bernsen
    Klazina Kooiman
    Marcel Segbers
    Fijs W. B. van Leeuwen
    Marion de Jong
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 579 - 596
  • [44] Ovarian cancer: Predictors of early death
    Urban, R. R.
    He, H.
    Alfonso, R.
    Hardesty, M. M.
    Goff, B. A.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 180 - 180
  • [45] Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (Review)
    Chuthapisith, Suebwong
    Eremin, Jennifer M.
    Eremin, Oleg
    ONCOLOGY REPORTS, 2008, 20 (04) : 699 - 703
  • [46] Comprehensive evaluation of cell death-related genes as novel diagnostic biomarkers for breast cancer
    Shi, Xiaoyue
    Ding, Hao
    Tao, Jing
    Zhu, Yanhui
    Zhang, Xiaoqiang
    He, Gao
    Yang, Junzhe
    Wu, Xian
    Liu, Xiaoan
    Yu, Xiafei
    HELIYON, 2023, 9 (11)
  • [47] The Distribution Analysis of the Biomarkers on Breast Cancer Tissues by Hadamard Transform Spectral Microscopic Imaging
    Xu Hao
    Chen Chuang
    Liu Chun-mei
    Peng Jun
    Li Yan
    Zhang Zhi-ling
    Tang Hong-wu
    SPECTROSCOPY AND SPECTRAL ANALYSIS, 2009, 29 (12) : 3216 - 3219
  • [48] Highly multiplexed imaging reveals prognostic immune and stromal spatial biomarkers in breast cancer
    Eng, Jennifer R.
    Bucher, Elmar
    Hu, Zhi
    Walker, Cameron R.
    Risom, Tyler
    Angelo, Michael
    Gonzalez-Ericsson, Paula
    Sanders, Melinda E.
    Chakravarthy, A. Bapsi
    Pietenpol, Jennifer A.
    Gibbs, Summer L.
    Sears, Rosalie C.
    Chin, Koei
    JCI INSIGHT, 2025, 10 (03)
  • [49] Imaging and Receptor Status as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Fasola, C. E.
    Godette, K. D.
    McDonald, M. W.
    O'Regan, R. M.
    Zelnak, A. B.
    Holmes, L. R.
    Landry, J. C.
    Torres, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S210 - S210
  • [50] A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine:: Breast tissue, imaging, and serum and urine biomarkers
    Fabian, CJ
    Kimler, BF
    Brady, DA
    Mayo, MS
    Chang, CHJ
    Ferraro, JA
    Zalles, CM
    Stanton, AL
    Masood, S
    Grizzle, WE
    Boyd, NF
    Arneson, DW
    Johnson, KA
    CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3105 - 3117